Potential radiation-sensitizing effect of semisynthetic epothilone B in human lung cancer cells

Jae Chul Kim, Jae Sung Kim, Debabrata Saha, Qianwen Cao, Yu Shyr, Hak Choy

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background and purpose: To evaluate a semisynthetic epothilone B, BMS-247550, as a potential radiosensitizer in vitro and in vivo. Materials and methods: Human NCI-H460 lung cancer cells were treated with either BMS-247550 or paclitaxel and in combination with radiation at multiple doses for different time periods. Surviving fractions were then analyzed using a clonogenic assay. Cell cycle redistribution by BMS-247550 was measured with propidium iodide and flow cytometry. Percent apoptosis was also measured using 7-amino-actinomycin D staining with flow cytometry. For in vivo studies, the H460 xenograft model was used in athymic nude mice. Tumors were treated with BMS-247550 (5 mg/kg) i.p. injection on days 0, 2, and 4 and/or radiation (2 Gy/day, days 0-4). Results: The in vitro radiation dose enhancement ratios (DER) of 1-h BMS-247550 and paclitaxel were 2.03 and 1.34, respectively. Treatment with BMS-247550 enhanced the G2/M block and induced apoptosis; whereas in combination with radiation, the induction of apoptosis was additive. BMS-247550 in combination with radiation in vivo enhanced the tumor growth delay when compared with either drug or radiation alone. Conclusions: These results demonstrated that BMS-247550 could enhance the effects of radiation in human lung cancer cells both in vitro and in vivo and that a G2/M block and increased apoptosis might be possible explanations for the enhancement.

Original languageEnglish (US)
Pages (from-to)305-313
Number of pages9
JournalRadiotherapy and Oncology
Volume68
Issue number3
DOIs
StatePublished - Sep 2003

Fingerprint

Radiation-Sensitizing Agents
Lung Neoplasms
Radiation
Apoptosis
Paclitaxel
Nude Mice
Flow Cytometry
Radiation Dosage
ixabepilone
epothilone B
Propidium
Radiation Effects
Heterografts
Neoplasms
Cell Cycle
Staining and Labeling
Injections

Keywords

  • Epothilone B
  • Lung cancer
  • Radiation

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Urology

Cite this

Potential radiation-sensitizing effect of semisynthetic epothilone B in human lung cancer cells. / Kim, Jae Chul; Kim, Jae Sung; Saha, Debabrata; Cao, Qianwen; Shyr, Yu; Choy, Hak.

In: Radiotherapy and Oncology, Vol. 68, No. 3, 09.2003, p. 305-313.

Research output: Contribution to journalArticle

Kim, Jae Chul ; Kim, Jae Sung ; Saha, Debabrata ; Cao, Qianwen ; Shyr, Yu ; Choy, Hak. / Potential radiation-sensitizing effect of semisynthetic epothilone B in human lung cancer cells. In: Radiotherapy and Oncology. 2003 ; Vol. 68, No. 3. pp. 305-313.
@article{55d81ae3a34e4eb69a0e192711f5b936,
title = "Potential radiation-sensitizing effect of semisynthetic epothilone B in human lung cancer cells",
abstract = "Background and purpose: To evaluate a semisynthetic epothilone B, BMS-247550, as a potential radiosensitizer in vitro and in vivo. Materials and methods: Human NCI-H460 lung cancer cells were treated with either BMS-247550 or paclitaxel and in combination with radiation at multiple doses for different time periods. Surviving fractions were then analyzed using a clonogenic assay. Cell cycle redistribution by BMS-247550 was measured with propidium iodide and flow cytometry. Percent apoptosis was also measured using 7-amino-actinomycin D staining with flow cytometry. For in vivo studies, the H460 xenograft model was used in athymic nude mice. Tumors were treated with BMS-247550 (5 mg/kg) i.p. injection on days 0, 2, and 4 and/or radiation (2 Gy/day, days 0-4). Results: The in vitro radiation dose enhancement ratios (DER) of 1-h BMS-247550 and paclitaxel were 2.03 and 1.34, respectively. Treatment with BMS-247550 enhanced the G2/M block and induced apoptosis; whereas in combination with radiation, the induction of apoptosis was additive. BMS-247550 in combination with radiation in vivo enhanced the tumor growth delay when compared with either drug or radiation alone. Conclusions: These results demonstrated that BMS-247550 could enhance the effects of radiation in human lung cancer cells both in vitro and in vivo and that a G2/M block and increased apoptosis might be possible explanations for the enhancement.",
keywords = "Epothilone B, Lung cancer, Radiation",
author = "Kim, {Jae Chul} and Kim, {Jae Sung} and Debabrata Saha and Qianwen Cao and Yu Shyr and Hak Choy",
year = "2003",
month = "9",
doi = "10.1016/S0167-8140(03)00200-7",
language = "English (US)",
volume = "68",
pages = "305--313",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Potential radiation-sensitizing effect of semisynthetic epothilone B in human lung cancer cells

AU - Kim, Jae Chul

AU - Kim, Jae Sung

AU - Saha, Debabrata

AU - Cao, Qianwen

AU - Shyr, Yu

AU - Choy, Hak

PY - 2003/9

Y1 - 2003/9

N2 - Background and purpose: To evaluate a semisynthetic epothilone B, BMS-247550, as a potential radiosensitizer in vitro and in vivo. Materials and methods: Human NCI-H460 lung cancer cells were treated with either BMS-247550 or paclitaxel and in combination with radiation at multiple doses for different time periods. Surviving fractions were then analyzed using a clonogenic assay. Cell cycle redistribution by BMS-247550 was measured with propidium iodide and flow cytometry. Percent apoptosis was also measured using 7-amino-actinomycin D staining with flow cytometry. For in vivo studies, the H460 xenograft model was used in athymic nude mice. Tumors were treated with BMS-247550 (5 mg/kg) i.p. injection on days 0, 2, and 4 and/or radiation (2 Gy/day, days 0-4). Results: The in vitro radiation dose enhancement ratios (DER) of 1-h BMS-247550 and paclitaxel were 2.03 and 1.34, respectively. Treatment with BMS-247550 enhanced the G2/M block and induced apoptosis; whereas in combination with radiation, the induction of apoptosis was additive. BMS-247550 in combination with radiation in vivo enhanced the tumor growth delay when compared with either drug or radiation alone. Conclusions: These results demonstrated that BMS-247550 could enhance the effects of radiation in human lung cancer cells both in vitro and in vivo and that a G2/M block and increased apoptosis might be possible explanations for the enhancement.

AB - Background and purpose: To evaluate a semisynthetic epothilone B, BMS-247550, as a potential radiosensitizer in vitro and in vivo. Materials and methods: Human NCI-H460 lung cancer cells were treated with either BMS-247550 or paclitaxel and in combination with radiation at multiple doses for different time periods. Surviving fractions were then analyzed using a clonogenic assay. Cell cycle redistribution by BMS-247550 was measured with propidium iodide and flow cytometry. Percent apoptosis was also measured using 7-amino-actinomycin D staining with flow cytometry. For in vivo studies, the H460 xenograft model was used in athymic nude mice. Tumors were treated with BMS-247550 (5 mg/kg) i.p. injection on days 0, 2, and 4 and/or radiation (2 Gy/day, days 0-4). Results: The in vitro radiation dose enhancement ratios (DER) of 1-h BMS-247550 and paclitaxel were 2.03 and 1.34, respectively. Treatment with BMS-247550 enhanced the G2/M block and induced apoptosis; whereas in combination with radiation, the induction of apoptosis was additive. BMS-247550 in combination with radiation in vivo enhanced the tumor growth delay when compared with either drug or radiation alone. Conclusions: These results demonstrated that BMS-247550 could enhance the effects of radiation in human lung cancer cells both in vitro and in vivo and that a G2/M block and increased apoptosis might be possible explanations for the enhancement.

KW - Epothilone B

KW - Lung cancer

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=1542781317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542781317&partnerID=8YFLogxK

U2 - 10.1016/S0167-8140(03)00200-7

DO - 10.1016/S0167-8140(03)00200-7

M3 - Article

VL - 68

SP - 305

EP - 313

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 3

ER -